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Staying current on literature related to antimicrobial stewardship can be challenging given the ever-increasing number of published 
articles. The Southeastern Research Group Endeavor (SERGE-45) identified antimicrobial stewardship–related peer-reviewed lit-
erature that detailed an actionable intervention for 2019. The top 13 publications were selected using a modified Delphi technique. 
These manuscripts were reviewed to highlight the actionable intervention used by antimicrobial stewardship programs to provide 
key stewardship literature for teaching and training and to identify potential intervention opportunities within one’s institution.
Keywords:  antibiotics; antimicrobial stewardship; infectious diseases; metrics; resistance.
Antimicrobial stewards and infectious diseases (ID) clinicians 
experienced important advances throughout 2019. Included 
among the new antimicrobial approvals by the Food and Drug 
Administration were new agents to combat multidrug-resistant 
(MDR) gram-negative infections (cefiderocol and imipenem/
cilastatin/relebactam), community-acquired pneumonia with 
a novel mechanism of action (lefamulin), and MDR tubercu-
losis (pretomanid) [1]. While the advent of new agents brings 
hope in managing difficult-to-treat infections, positioning 
these new drugs on formularies and in treatment decisions re-
mains a constant challenge for stewardship teams. Additionally, 
several pharmaceutical companies continue to struggle with 
or abandon the antimicrobial market as sales of new agents 
flounder, which calls into question the future of novel anti-
microbial approvals [2, 3].
The year brought mixed news regarding antimicro-
bial resistance rates. As reported by the Centers for Disease 
Control and Prevention (CDC) in the 2019 edition of the 
Antibiotic Resistance Threats report, proportions of traditional 
hospital-acquired infections such as MDR Pseudomonas 
aeruginosa and Acinetobacter baumannii declined, per-
haps owing to the impact of acute care stewardship teams 
meeting CDC core elements [4–6]. In contrast, the propor-
tion of extended-spectrum beta-lactamase (ESBL)–producing 
Escherichia coli increased, emphasizing the need for focused 
stewardship efforts outside the hospital walls [4]. Reducing un-
necessary antimicrobial prescriptions and overall antimicrobial 
utilization remain valued metrics and pillars for successful anti-
microbial stewardship teams to combat the untoward effects of 
antimicrobials [7].
The body of literature continues to grow, offering new ideas 
and strategies along with supporting data reinforcing tradi-
tional interventions for antimicrobial stewardship teams. Since 
2016, members of the Southeastern Research Group Endeavor 
(SERGE-45), an interprofessional research network primarily 
composed of expert pharmacist stewards in the Southeastern 
United States, has systematically compiled and reviewed pub-
lications involving an antimicrobial stewardship intervention 
annually [8–11]. The top 13 selected articles from 2019 are de-
tailed herein and briefly reviewed in Table 1 [12–24].
METHODS
Using a modified Delphi technique (detailed previously), mem-
bers of the SERGE-45 network identified antimicrobial stew-
ardship publications from 2019 considered to be significant 
using the following inclusion criteria: (1) published in 2019, in-
cluding electronic, “early-release” publications, and (2) included 
an actionable intervention [25]. An actionable intervention 
was defined as a stewardship strategy that was implemented in 






/ofid/article/7/10/ofaa402/5902822 by guest on 10 M
arch 2021
2 • ofid • Stover et al
Table 1. Summary of Top 13 Antimicrobial Stewardship Intervention Papers, 2019









experimental study in a large aca-
demic medical center comparing 
adherence to an institutional SAB 
management bundle
Upon isolating Staphylococcus aureus 
from blood cultures, clinical deci-
sion support software triggered an 
automated, hard-stop alert in the 
electronic health record prompting 
providers to use a 6-component 
SAB bundle, which consisted of (1) 
infectious diseases consultation, 
(2) source control, (3) echocardio-
gram, (4) repeat blood cultures, (5) 
antimicrobial therapy, and (6) appro-
priate duration.
Primary outcome:
-Adherence to all 6 components of SAB bundle: 29.7% vs 56.9%; 
P < .001
Secondary outcomes:
-ID consult within 5 days of positive culture: 76.6% vs 88.8%; 
P = .021
-Source control: 54.1% vs 79.3%; P < .001
-Repeat blood cultures within 72 hours of initial positive: 98.2% 
vs 100%; P = .238
-Echocardiogram: 76.6% vs 83.6%; P = .244
-Antimicrobial therapy: 94.6% vs 96.6%; P = .532
-Appropriate duration: 80.2% vs 83.6%; P = .605
-30-day all-cause mortality: 12.6% vs 6%; P = .110









Retrospective, single-center cohort 
study comparing a pre-antimicrobial 
stewardship period with a 
postantimicrobial stewardship 
period 
Antimicrobial stewardship bundle 
in conjunction with rapid diag-
nostic testing for uncomplicated 
gram-negative bacteremia: pro-
moting IV-to-PO switches, 7-day 
antibiotic durations, advising against 
repeat blood cultures. This is com-
pared with a pre-antimicrobial 
stewardship period with only rapid 
diagnostic testing available.
Primary outcome:
-Shorter median treatment duration in the ASP bundle group (10 
vs 14 days; P < .001)
Secondary outcomes:
-Earlier switch to PO therapy (day 4 vs day 5; P = .046)
-Lower 30-day all-cause readmission (23.3% vs 39.2%; P = .047)
-Lower incidence of repeat blood cultures (44.2% vs 66.7%; 
P = .01)








series study across 214 primary 
health centers in 4 primary health 
care districts
Education that focused on 5 aspects: Primary outcomes:
1. Central and local dissemination of 
program information
-Inappropriate antibiotic prescribing had an annual change of 
3.2% (36.5% in 2014 to 26.9% in 2017; P = .001)
2. Open online courses focused on 
appropriate antibiotics for common 
infections
Incidence density of ESBL-producing E coli in urine cultures: RR 
–65.6% 4 years after start of program:
3. Regular in-person clinical protocol 
updates
-Pre-intervention (2012–2013) increase: 0.004 cases per 1000 
inhabitants; P < .0001
4. Educational interviews -Intervention (2014–2017) decrease: –0.006 cases per 1000 inhab-











A C. difficile NAAT ASP pre-
authorization and chart review was 
initiated in October 2016. A pre-
implementation period of January 
2014 to September 2016 was com-
pared with a postimplementation 
period of October 2016 to April 
2018. The ASP pharmacist pro-
spectively reviewed all weekday 
C. difficile NAAT orders and 
provided recommendations for 
canceling those that did not meet 
testing criteria.
Primary outcome: pre-implementation vs postimplementation
-Mean monthly NAAT, 15.4 vs 12.4; P = .018
Secondary outcomes: pre-implementation vs postimplementation
-HO-CDI-IR, 8.5 vs 6.4 per 10 000 patient days; P = .0036
-SIR, 0.97 vs 0.78; P = .015







Retrospective, multicenter cohort 
study
Risk of CDI was examined in adults 
hospitalized for >48 hours for the 
treatment of Enterobacterales 
bloodstream infections.
Primary outcome:
-Higher incidence of CDI in patients who received >48 hours of 
APBL: 7.0% (95% CI, 4.2% to 9.8%) vs 1.8% (95% CI, 0.4% 
to 3.2%) in patients who received ≤48 hours of APBL; log-rank 
P = .002
Secondary outcomes:
- Receipt of >48 hours of APBL was associated with an HR of 
developing CDI of 3.56 (95% CI, 1.48 to 9.92); P = .004
-End-stage renal disease was associated with an HR of devel-
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Retrospective, single-center cohort 
study evaluating impact of an ARV 
stewardship team on identification 
and correction of ARV medication 
errors
Medication reconciliation and daily 
review of ARV medications 
throughout inpatient admission by 
an interdisciplinary pharmacist–phy-
sician ARV stewardship team. In-
cluded contact with outpatient HIV 
providers for regimen confirmation 
and standardized communication 
with the primary team via docu-
mentation in the EHR.
Primary outcome:
-336 interventions made by ARV stewardship team over 
12-month period; drug interaction (45.2%), incorrect regimen 
(17.9%), and OI prophylaxis (10.1%) errors occurred most fre-
quently
Secondary outcomes:
-43.2% of hospitalizations with ARV orders required at least 1 
intervention
-96.4% intervention acceptance rate
-$263 428 estimated associated cost savings
-Multivariable analysis identified multitablet inpatient regimen 
(P = .009), ICU admission (P = .01), surgical care (P = .02), 
days reviewed (P = .02), and noninstitutional HIV provider 








Pre/post design over a 4-year 
period examining impact of a 
high-intensity, interdisciplinary, 
round-based PAF compared with a 
low-intensity PAF on antimicrobial 
use measured in DDD per 1000 
PD on internal medicine wards in a 
400-bed community hospital 
Pre-intervention: low-intensity phase 
24 months before the intervention
Primary outcomes:
-ASP pharmacists provided PAF to 
prescribers on 5 internal medicine 
units; focus on patients receiving 
targeted antibiotics
-Low-intensity phase antimicrobial use: 483 DDD/1000PD vs 442 
DDD/1000PD in high intensity (difference, –42; 95% CI, –74 
to –9)
-1-on-1 recommendation to the 
internal medicine physician per-
formed for each patient requiring 
intervention
-Adjusted analysis to account for seasonality (difference, –93 
DDD/1000PD; 95% CI, –169 to –20)
Postintervention: high-intensity phase 
24 months
Secondary outcomes:
-Structured, twice-weekly ASP rounds Adjusted analysis to account for seasonality: postintervention 
period:
-Interdisciplinary team (ward pharma-
cist, internal medicine physician, 
ASP pharmacist, and ASP physician) 
rounded for 30 minutes per unit
-Months 1–12, 483.3 DDD/1000PD in low-intensity group vs 
458.3 DDD/1000PD in high-intensity group (difference, –75.3; 
95% CI, –145.9 to –5.9)
-Internal medicine physician made 
final decision after PAF recommen-
dation
-Months 13–24 in low-intensity group 483.3 DDD/1000PD vs 
high-intensity group 415.5 DDD/1000PD (difference, –121.5; 
95% CI, –217 to –28.3)
Targeted antibiotics:
-153.1 DDD/1000PD in low-intensity vs high-intensity group 141 
DDD/1000 PD (difference, –50.1; 95% CI, –71.7 to –28)
-No changes in clinical outcomes of CDI, readmission rate, or 








Retrospective study evaluating anti-
biotic usage comparing traditional 
ASP PAF with implementation of 
an ADAP
Implemented an automatic antibiotic 
discontinuation policy of antibiotics 
authorizing ASP team to stop 
antibiotics therapy in cases with 
inappropriate duplicate antimicro-
bial coverage (atypical, anaerobic, 
dual-β-lactam without documented 
rational) or excess duration of 
therapy in specified disease states/
or antibiotics >48 hours and no 
documented infection
Primary outcome:
-Mean total antibiotic days per patient (7.6 days vs 6.6 days; 
P < .05)
Secondary outcome:
-Mean excess days of antibiotics (2.3 days vs 1.5 day; P < .05)
-Patients prescribed antibiotics at discharge (18.5% vs 8%; 
P < .05)
-30-day readmission (12.3% vs 14.2%; NS)
-CDI (1 vs 2 cases; NS)






Multicenter, quasi-experimental,  
pre- and postintervention study
Review of patients on broad-spectrum 
antimicrobials and those admitted 
with lower respiratory tract infec-
tions and skin and soft tissue infec-
tions by remote ID physicians and 
local pharmacists
Primary outcomes:
-A total of 1419 recommendations were made, of which 1262 
(88.9%) were accepted
-Decrease in tier 1 antimicrobial use (DOT/1000 PD): 10.6 during 
the intervention period vs 16.3 in historical control; P = .04
-Decrease in tier 2 antimicrobial use (DOT/1000 PD): 248.2 during 
the intervention period vs 325.9 in historical control; P < .001
-Numerical decrease in total antimicrobial use (DOT/1000 PD): 
820.7 during the intervention period vs 777.1 in historical con-
trol; P = .18
-Increase in ID consultations/1000 PD: 21.5 during the interven-
tion period vs 15.4 in historical control; P = .001
-Estimated annual cost-savings: $104 087.34 on tier 1 antimicrobials 
and $56 239.05 on tier 2 antimicrobials vs increase of $17 696.55 
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Multicenter, historically controlled, 
prospective, nonrandomized clinical 
trial with crossover design
Modified PA by pharmacists 
and PPR by the stewardship 
team targeting vancomycin, 
piperacillin-tazobactam, and the 
antipseudomonal carbapenems on 
formulary
Primary outcomes:
-Intervention approval processes took a median of 95 days
-Pharmacists performed 1456 interventions (median per hospital, 
350) during PA and 1236 interventions (median per hospital, 
298) during PPR
-Recommendations were accepted by clinicians in 79.2% of 
cases during PA and 69.0% during PPR
-More study antibiotics were determined to be inappropriate 
during PPR: 41.0% during PPR vs 20.4% during PA; P < .001
-Pharmacists recommended de-escalation more during PPR: 
29.1% during PPR vs 13.0% during PA; P < .001
-Pharmacists recommended dose change more during PA: 15.9% 
during PA vs 9.6% during PPR; P < .001
-The median time dedicated to the stewardship interventions 
varied by hospital (range of median hours per week, 5–19)
Secondary outcomes:
-No decrease in antibiotic use (DOT/1000 PD) during PA: 931.0 vs 
926.6 during matched historical control (difference, 4.4; 95% 
CI, –55.8 to 64.7)
-Decrease in antibiotic use (DOT/1000 PD) during PPR: 925.2 vs 
965.3 during matched historical control (difference, –40.1; 95% 
CI, –71.7 to –8.6)
-Same median length of hospitalization per admission for PA, 








Implementation of antimicrobial 
stewardship in an academic dental 
practice using the CDC Core Elem-
ents of Outpatient Antimicrobial 
Stewardship 
Multimodal intervention consisting of 
standardizing antimicrobial therapy 
for acute dentoalveolar conditions, 
educational interventions, and 
patient-facing educational posters 
focusing on the necessity of anti-
biotics and potential harms
Primary outcome:
-72.9% decrease in antibiotic prescribing rate per urgent care visit 
(pre-intervention urgent care prescribing rate, 8.5% [24/283]; 







pre- and postimplementation of 2 
antimicrobial stewardship interven-
tions in an inpatient hematological 
malignancy treatment unit
Utilized monthly antibiotic cycling with 
either piperacillin-tazobactam or 
cefepime (with or without metroni-
dazole) and a previously described 
clinical prediction tool to guide em-
piric VRE therapy when managing 
febrile neutropenia
Primary outcomes:
-Carbapenem use decreased by 230 DOT/1000 PD (95% CI, −290 
to −180; P < .001)
-Unadjusted antipseudomonal carbapenem use decreased after 
intervention (396.5 vs 123.4 DOT/1000 PD; P < .001)
-Daptomycin prescribing (−160 DOT/1000 PD; 95% CI, −200 to 
−120; P < .001)
-VRE clinical prediction score (−30 DOT/1000 PD; 95% CI, −50 to 0; P = .08)
Secondary outcomes:
-VRE colonization (OR, 0.64; 95% CI, 0.51 to 0.81; P < .001) 
and infection decreased after intervention (2.38 vs 1.08 infec-
tions/1000 PD; P = .006)
-Infection due to ESBL-producing Enterobacteriaceae increased 
(0.14 to 0.81/1000 PD; P = .01) postintervention






Pre/post quasi-experimental study 
evaluating impact of novel anti-
microbial use visualization tools on 
antimicrobial usage at 8 VA inpatient 
facilities
Development of interactive graphic tools 
for dissemination of in-depth facility-
level antimicrobial usage data to 
facility stewards. The tools were op-
timized based on collaborative feed-
back from the 8 volunteer facilities 
and ultimately provided dashboards 
that could be filtered by antimicro-
bial use decision point, antimicrobial 
agent type, unit, disease state, or 
SAAR category and compared with 
similar or all VA facilities. Change 
in antimicrobial use was assessed 
pre-intervention (January 2014–Jan-
uary 2016) and postintervention (July 
2016–January 2018).
Average change in DOT/1000 DP at intervention vs noninterven-
tion sites
Primary outcome:
-Total inpatient antimicrobial use: –2.1% (95% CI, –5.7% to 1.6%; 
P = .2529) vs +2.5% (95% CI, 0.8% to 4.1%; P = .0026); abso-
lute difference, 4.6% (P = .025)
Secondary outcomes:
-Total inpatient use of anti-MRSA agents: –11.3% (95% CI, 
–16.0% to –6.3%; P < .0001) vs –6.6% (95% CI, –9.1% to 
–3.9%; P < .0001); absolute difference, 4.7% (P = .092)
-Total inpatient use of antipseudomonal agents: –3.4% (95% CI, 
–8.2% to 1.7%; P = .185) vs +3.6% (95% CI, 0.8% to 6.5%; 
P = .011); absolute difference, 7.0% (P = .018)
Abbreviations: ADAP, automatic discontinuation of antibiotics policy; APBL, antipseudomonal β-lactam; ARV, antiretroviral; ASP, antimicrobial stewardship programs; CDC, Centers for Disease Control 
and Prevention; CDI, Clostridioides difficile infection; DDD, defined daily dose; DOT, days of therapy; DP, days present; EHR, electronic health record; HO, hospital-onset; HR, hazard ratio; ICU, intensive 
care unit; ID, infectious diseases; IQR, interquartile range; IR, incident rate; IV, intravenous; MRSA, methicillin-resistant Staphylococcus aureus; NAAT, nucleic acid amplification tests; NS, nonsignificant; 
OI, opportunistic infection; OR, odds ratio; PA, preauthorization; PAF, prospective audit and feedback; PD, patient-days; PO, per oral; PPR, postprescription audit and review; RR, relative reduction; SAAR, 
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practice and resulted in measurable outcomes. Clinical prac-
tice guidelines, official statements, review articles, and articles 
without an actionable intervention were excluded.
A PubMed search using “antimicrobial stewardship” for 
2019 revealed 1293 potential publications. P.B.B. screened ab-
stracts to ensure that all relevant articles were considered. In 
addition, 79 author-identified publications (most duplicated 
from the literature search) were submitted for potential inclu-
sion. C.M.B., K.R.S., and P.B.B.  screened these to ensure that 
articles met inclusion criteria. During the first round of re-
views, a total of 60 articles were distributed to the SERGE-45 
network (65 members) for ranking using SurveyMonkey based 
on contribution and/or application to antimicrobial steward-
ship programs (ASPs); 21 participants (32%) ranked their top 
13 based on clinical judgment [26]. During the second round, 
12 authors (100%) ranked their top 13 based on clinical judg-
ment. Finally, in a teleconference C.M.B., K.R.S., and P.B.B. re-
viewed the group ranks and established final consensus on the 
top 13 articles based on number of votes received for each ar-
ticle, described herein. Figure 1 is a flowchart of the database 
and article selection process, and Table 1 is a summary of the 
selected articles.
RESULTS
Automated Stewardship Intervention for Staphylococcus aureus 
Bloodstream Infection
Management of Staphylococcus aureus (SA) bloodstream in-
fection (BSI) remains challenging, with mortality rates around 
20% [27]. Furthermore, adherence to evidence-based recom-
mendations for managing SABSI continues to be suboptimal. 
Brotherton and colleagues conducted a single-center, retrospec-
tive quasi-experimental study to evaluate rates of adherence 
and clinical outcomes after implementing an SABSI manage-
ment bundle [12]. The intervention used an automatic, hard-
stop alert in the electronic health record directing providers to 
use an electronic order set after detection of SABSI. Providers 
were required to utilize the order set or provide a reason for 
dismissing the alert. In addition, brief educational sessions re-
garding guideline location and bundle elements were provided 
before implementation.
In total, 227 patients were included (111 in the pre-
intervention group compared with 116 in the postintervention 
group), of which almost all were complicated SABSI (97.3% 
vs 92.2%, respectively; P = .136). Adherence to all compo-
nents of the bundle occurred significantly more often in the 
postintervention group (Table  1). In the postintervention 
group, the median time to repeat blood cultures and steriliza-
tion of blood cultures was significantly shorter, and the me-
dian time from SABSI identification to alert activation was 0.5 
hours. Despite alert activation occurring in 95.7% of cases in 
the postintervention group, the order set was utilized in only 
57.8%. No differences in hospital length of stay, 30-day mor-
tality, or 90-day readmission for SABSI complications were ob-
served between groups.
As opposed to other SABSI management bundles requiring 
prospective audit with intervention and feedback, this study re-
inforces the possibility of utilizing an automated antimicrobial 
stewardship intervention to improve management. Although 
high rates of adherence to individual components of the bundle 
were observed, adherence to all components remained low.
Impact of a Stewardship Bundle on Gram-Negative Bacteremia
The literature for gram-negative BSI has significantly changed 
treatment recommendations by supporting shorter treat-
ment durations [28], early switch to oral antibiotics [29], and 
demonstrating lack of benefit of repeat blood cultures [30]. 
Using an approach that is well described in gram-positive in-
fections, Erickson and colleagues conducted a single-center, 
retrospective cohort evaluation of an antimicrobial stewardship 
bundle coupled with rapid diagnostic tests (RDTs) for uncom-
plicated gram-negative bacteremia [13]. The prestewardship 
group did not have an active stewardship intervention, whereas 
the poststewardship group had 0.5 full-time equivalent (FTE) 
physicians and 1 FTE pharmacist to implement the bundle, 
which included intravenous-to-oral (IV-to-PO) antibiotic 
switches, 7-day antibiotic durations, and avoidance of repeat 
blood cultures. Patients with uncomplicated gram-negative 
bacteremia (monomicrobial, with source control, and no im-
munosuppression or indications for longer duration of therapy) 
managed with active therapy within the first 24 hours were eli-
gible for inclusion.
The main infection source was the urinary tract, and the most 
common organism was E. coli. The poststewardship group had a 
shorter median duration of antibiotic therapy, and patients were 
switched to oral antibiotics sooner, had fewer repeat cultures 
obtained, and had a lower 30-day readmission rate. Mortality 
and bacteremia recurrence were similar between the groups. 
This study demonstrated the efficacy of an antimicrobial stew-
ardship bundled approach coupled with rapid diagnostic testing 
for management of uncomplicated gram-negative bacteremia 
and further supports the safety of shorter durations of anti-
biotics in these patients.
Impact of Education in Primary Care on ESBL Escherichia coli in the 
Community
Education alone is noted to be a low-effectiveness stewardship 
strategy, unless it is combined with real-time intervention(s) 
[31]. Peñalva and colleagues evaluated the impact of structured 
and consistent educational efforts on rates of ESBL E.  coli in 
Spain [14]. The study spanned from January 2012 to December 
2017 (pre-intervention 2012–2013, intervention 2014–2017) 
and included 5 interventions (shown in Table  1). The educa-
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antibiotics was randomly selected, then the diagnosis and anti-
biotic course were reviewed with the prescriber and determined 
to be appropriate or inappropriate. Prescribers received an av-
erage of 5 interviews annually. Antibiotic consumption and 
ESBL incidence were assessed quarterly.
The study included 1 937 512 individuals seen by 1387 pre-
scribers, who underwent 24  150 educational interviews. 
Each year of the intervention period saw an 11% increase in 
interviews conducted and a 3.2% decrease in inappropriate 
prescribing (P = .001). The most common causes for an “inap-
propriate” prescription were agent selection (36.9%) and dura-
tion (34.5%). Decreases in use were identified for ciprofloxacin 
and cefuroxime, but not for third-generation cephalosporins. 
No changes were noted for levofloxacin and amoxicillin-
clavulanate, and increases were identified for amoxicillin and 
fosfomycin.
Susceptibilities were performed on 67  428 E.  coli isolates 
during the 6 years, with a significant change in the rate correl-
ating to the start of the intervention. Pre-intervention, the pro-
portion of ESBL-producing E. coli was 7.1%, and by the end of 
the intervention period it was 5.5% (P = .0001).
This study was supported and funded by the Spanish govern-
ment, marking high commitment within the European Union 
for antimicrobial stewardship. This study showed that con-
sistent educational contact impacts prescribing and decreases 
resistance, especially in the primary care environment where 
the majority of antibiotic prescribing occurs. Additionally, it 
took an important step toward linking decreased antibiotic con-
sumption to a meaningful outcome.
Diagnostic Stewardship and Clostridioides difficile Testing
RDTs are important tools for ASPs. The 2017 Infectious Diseases 
Society of America (IDSA) and Society for Healthcare and 
Epidemiology of America guidelines for Clostridioides difficile 
infections (CDIs) have specific recommendations for the use of 
nucleic acid amplification tests (NAATs) [32]. These include the 
use of either a multistep test involving NAAT, glutamate dehy-
drogenase (GDH), and/or toxins with NAAT, or NAAT alone 
with established testing criteria. However, inappropriate use of 
C. difficile RDTs may lead to false-positive results and the treat-
ment of asymptomatic patients.
Christensen and colleagues performed a quasi-experimental 
retrospective, single-center study evaluating ASP-led education 
and prior authorization on C. difficile NAATs [15]. The study 
had a pre-intervention period from January 2014 to September 
2016 and a postintervention period from October 2016 to April 
2018. During the postintervention period, an ASP pharmacist 
reviewed all weekday NAATs ordered on hospital day ≥4. Of 
note, this study used NAAT testing alone, not multistep testing. 
The ASP pharmacist evaluated clinical signs and symptoms 
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of CDI, recent NAAT results, administration of tube feeds, 
laxatives, stool softeners, or contrast dye in the preceding 24 
hours as well as imaging studies. Providers were contacted on 
all NAATs that did not meet preauthorization criteria and re-
commended to cancel the test. Of note, patients in the stem cell 
transplant unit were excluded.
The postintervention group had statistically significant im-
provement compared with the pre-intervention group with re-
gards to the mean hospital-onset CDI (HO-CDI), incident rate 
of HO-CDI, and standardized infection ratio. Interestingly, the 
consumption of oral vancomycin did not differ between the 2 
intervention periods. Overall, this study confirms that RDTs for 
CDI must be used in conjunction with ASP to be an effective 
patient care tool.
Early De-escalation of Antibiotic Therapy and Risk of Clostridioides 
difficile Infection
The association between use of broad-spectrum antibiotics and 
risk of CDI is well established [33]. Seddon and colleagues sought 
to determine the impact of early de-escalation of antipseudomonal 
β-lactam (APBL) antibiotics on the risk of CDI within 90 days in 
patients hospitalized for the treatment of Enterobacterales BSI 
in South Carolina [16]. Patients 18 years and older who had a 
first episode of monomicrobial BSI due to Enterobacterales from 
January 1, 2011, to June 30, 2015, who were identified through 
microbiology laboratory databases and who had a full 48-hour 
window for de-escalation of antibiotics were included. Patients 
who had a CDI within 1 year of BSI and those with concurrent 
CDI and BSI were excluded. A total of 808 patients were included 
(414 received >48 hours of APBL, 394 received ≤48 hours). E. coli 
was the most common bloodstream isolate (56%), followed by 
Klebsiella species (21%). The median time to CDI (interquar-
tile range) was 11 (4–27) days. The overall incidence of CDI was 
4.4% (95% CI, 2.8% to 6.0%), with significantly higher incidence 
of CDI in patients who received >48 hours of APBL than in those 
who received ≤48 hours of APBL. After adjustments for the pro-
pensity to receive >48 hours of APBL, end-stage renal disease and 
receipt of >48 hours of APBL remained independently associated 
with higher risk of CDI. This study showed that end-stage renal 
disease and receipt of APBL for >48 hours are associated with 
CDI in adults hospitalized for the treatment of Enterobacterales 
BSI. Therefore, appropriate empiric antibiotic selection and early 
de-escalation of APBL using clinical risk assessment tools or mo-
lecular RDT are likely to reduce the incidence of CDI in patients 
with Enterobacterales BSI.
Impact of an Inpatient Antiretroviral Stewardship Team
Errors in antiretroviral (ARV) medication prescribing, partic-
ularly at transitions of care, remain a prevalent patient safety 
issue, with reported rates as high as 86% [34]. DePuy and col-
leagues sought to determine if an ARV stewardship program 
(ARVSP) composed primarily of an HIV pharmacist specialist 
and ID physician would be able to identify and correct inpatient 
ARV medication errors [17]. The team reviewed ARV orders 
within 24 hours of admission and confirmed regimens with 
outpatient HIV providers as needed. A standardized commu-
nication was entered within the electronic health record (EHR) 
containing medication reconciliation notes and additional re-
commendations. A  daily profile review was completed for all 
patients throughout admission.
The overall 12-month error rate, medication error types, and 
subsequent intervention acceptance rate were consistent with 
other reports in the literature. However, there were several in-
novative ARVSP components to highlight in this study. This 
was the first published report of cost avoidance associated with 
an ARVSP. The interdisciplinary structure of the ARVSP was 
unique and mimicked the established model for robust ASPs. 
Daily profile review and standardized communication in the 
EHR facilitated ongoing error monitoring, expanded capture 
of intervention outcomes, and enhanced financial impact esti-
mation. Additionally, this study identified novel risk factors for 
ARV medication errors that can be applied to future ARVSP 
development and research.
High- vs Low-Intensity Prospective Audit and Feedback
A major core ASP strategy supported by the IDSA and CDC 
is prospective audit and feedback (PAF). While effective, PAF 
is typically labor-intensive, difficult to implement in resource- 
and/or workforce-limited settings, and relies on provider ac-
ceptance of recommendations [31, 35]. The current literature 
describes a wide variation in PAF designs that have attempted 
to overcome these disadvantages.
Langford and colleagues examined the impact of a high-
intensity, twice-weekly interdisciplinary rounds-based PAF 
compared with low-intensity (weekly review, 1-on-1 education) 
PAF on antimicrobial use in internal medicine wards in a 400-
bed community hospital over a 4-year period [18]. A reduction 
in the primary outcome of antimicrobial use was seen in the 
high-intensity phase as compared with the low-intensity phase, 
with a greater reduction in usage seen in the latter half of the 
high-intensity period. No change was seen in clinical outcomes 
of CDI, readmission rate, or mortality. The findings of this study 
highlight the benefit of “handshake stewardship,” a term first 
coined by Hurst and colleagues [36]. Although face-to-face 
rounds have proven impactful on antimicrobial use, the time 
requirements can be rate-limiting. Further studies are needed to 
evaluate the impact of workload requirements associated with 
high-intensity PAF to ensure appropriate return on investment 
for the time-intensive approach.
Effects of Automatic Antibiotic Discontinuation
As described above, PAF is a fundamental strategy utilized by 
ASP that engages providers after an antibiotic is prescribed [31]. 
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traditional ASP PAF with an ASP-led automatic discontinua-
tion of antibiotics policy (ADAP) in an 800-bed, tertiary care 
academic teaching hospital [19]. The policy targeted duplicate 
therapy, defined as unnecessary double anaerobic, atypical, 
and/or β-lactam agents without documented rationale and ex-
cessive durations of therapy for prespecified disease states ex-
ceeding evidence-based recommendations. Antibiotics for >48 
hours without a documented infection were also included in 
the ADAP. Education on the ADAP scope was provided via the 
pharmacy and therapeutics committee, and the ASP team docu-
mented ADAP interventions with written notes. An ID-trained 
physician and ID-trained pharmacist comprised the ASP team.
The most common diagnoses encountered in the pre- and 
post-ADAP groups were pneumonia, complicated cystitis, and 
chronic obstructive pulmonary disease exacerbation. Excess 
duration of therapy (73.5% vs 62.3%), followed by antibiotics 
without an indication (18.5% vs 22.2%), was the most fre-
quent reason for ASP intervention. The mean total number of 
antibiotic days per patient and the percentage of patients dis-
charged on antibiotics were reduced post-ADAP. There was a 
nonsignificant increase in 30-day readmission after ADAP; 
however, readmission rate due to an infectious diseases diag-
nosis was higher in the pre-ADAP group (65% vs 39%).
This single-center study demonstrated that an ASP-led 
ADAP can reduce overall in- and outpatient antibiotic use 
without increasing adverse patient outcomes. However, in 
settings where ID-trained personnel are not readily available, 
approval and implementation of this type of policy may be dif-
ficult to achieve.
Telehealth-Based ASP in Community Hospitals
Community hospitals often have less access to ID expertise and 
are less likely to have robust ASPs than academic medical cen-
ters [37]. Shively and colleagues sought to describe the practical 
implementation and assess the effectiveness of a telehealth-
based ASP (TeleASP) in 2 community hospitals using the ex-
pertise of a large health network in Pennsylvania [20]. On-site 
hospitalists, advanced practice providers, and pharmacists 
were trained by ID physicians and ID/ASP pharmacists from 
within the large network. On-site providers were permitted to 
order tier 1 antimicrobials for 24 hours, after which they could 
be continued only with TeleASP or local ID approval. Tier 2 
antimicrobials were not restricted but were monitored via PAF 
during weekdays. There was no restriction or audit and feed-
back on nontiered antimicrobials unless they were encountered 
by the TeleASP team in review of eligible patients. A review of 
patients on broad-spectrum antimicrobials and those admitted 
with select common infections was performed by remote ID 
physicians who discussed patients by telephone with local phar-
macists. Following the call, local pharmacists communicated 
the interventions to primary teams. Antimicrobial use was col-
lected for 12  months before TeleASP implementation and for 
6 months after implementation. The majority of recommenda-
tions made were accepted by the local clinicians. The most fre-
quent type of intervention was de-escalation of antimicrobial 
therapy. Tier 1 and tier 2 antimicrobial use decreased signifi-
cantly during the intervention period compared with historical 
control, while nontiered antimicrobial use increased. Local ID 
consultations increased significantly during the intervention 
period compared with historical control. The program led to 
substantial cost-savings largely from an overall decrease in anti-
microbial use. This study showed that a TeleASP in community 
hospitals is likely to result in reduction in broad-spectrum anti-
microbial use, increase in ID consultations, and reduction in 
antimicrobial expenditures.
Core Antibiotic Stewardship Interventions in Community Hospitals
Antimicrobial stewardship guidelines recommend the imple-
mentation of preauthorization (PA) and/or PAF as the core 
components of any ASP [31]. Anderson and colleagues sought 
to determine the feasibility of implementing modified PA and 
postprescription audit and review (PPR) in 4 community hos-
pitals in North Carolina [21, 38]. The modified PA consisted of 
a trained pharmacist reviewing all study antibiotic prescriptions 
for approval during weekday study hours, and PPR consisted of 
the stewardship team reviewing eligible prescriptions between 
48 and 96 hours after order entry. Hospitals were paired based 
on size, and 1 hospital from each pair was assigned to a modified 
PA for 6 months, then transitioned to PPR for 6 months after a 
1-month washout. The other 2 hospitals were assigned to PPR 
for 6 months, then transitioned to modified PA for 6 months 
after a 1-month washout. Antibiotics targeted were vanco-
mycin, piperacillin-tazobactam, and the antipseudomonal 
carbapenems on formulary. Antibiotic use was collected for 
12 months before ASP implementation. An ID physician was 
available for consultation at 2 participating hospitals. Eligible 
patients were identified using lists generated from pharmacy 
prescription databases. Implementing the 2 core stewardship 
strategies was feasible, as evidenced by (1) approval of admin-
istration and committees at all study hospitals; (2) comple-
tion of pharmacist training; (3) initiation and implementation 
of interventions; and (4) documentation of time required for 
interventions. The majority of pharmacist recommendations 
were accepted by clinicians. Study antibiotics were deter-
mined to be inappropriate 2 times more often during the PPR 
period than during the PA period. Pharmacists recommended 
a dose change more often in the PA period and de-escalation 
more often in the PPR period. Antibiotic use did not decrease 
during the PA period; however, it decreased significantly com-
pared with matched historical control during the PPR period. 
Length of hospitalization did not change throughout the study. 
This trial showed that while strict PA is unlikely to be feasible 
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Implementing Antimicrobial Stewardship in an Academic Dental Practice
Dentists have become increasingly recognized as significant 
prescribers of antimicrobial therapy. It is estimated up to 10% 
of all outpatient antimicrobial prescriptions can be attributed 
to dentists, with clindamycin being most frequently prescribed 
[39]. However, best practices for antimicrobial stewardship in 
the area of dentistry are lacking.
In conjunction with an academic dental practice, Gross and 
colleagues sought to improve antimicrobial prescribing using 
the CDC Core Elements of Outpatient Antibiotic Stewardship 
[22, 40]. The University of Illinois at Chicago (UIC) College of 
Dentistry provides care for >30 000 patients annually. In addi-
tion, dentists in Illinois account for nearly 80 antibiotic pre-
scriptions per 1000 patients, thus illustrating an opportunity 
for intervention [41]. Leadership from both the University of 
Illinois Hospital and Health Sciences System ASP and the UIC 
College of Dentistry met and ultimately made the development 
of a dental ASP a strategic initiative. Baseline prescribing data 
cross-referenced with patient visit and dental coding were re-
viewed, and potential areas for improvement were identified. 
One particular area of concern was the number of prescriptions 
for acute dentoalveolar conditions in the urgent care clinic. The 
first practice intervention was to standardize antibiotic use for 
dentoalveolar conditions given feasibility via educational inter-
vention and subsequent impact. To support this intervention, 
an evidence-based clinical decision support tool was developed 
that provided drug selection and optimal duration of therapy. 
While this represents a single intervention, the successful out-
come as shown in Table 1 will facilitate expansion of the dental 
ASP to other areas in the future.
This study provides a template for other programs to utilize 
simple interventions to affect the prescribing of antimicrobials 
in the dental setting. Moreover, this study also highlights the 
effectiveness of collaboration between key stakeholders in dif-
ferent arenas as it pertains to stewardship.
Antimicrobial Stewardship in Patients With Cancer or Undergoing 
Hematological Stem Cell Transplant
Antimicrobial stewardship in patients with hematologic ma-
lignancy is challenging, as the optimal approach is not well 
defined. Implementation of stewardship interventions in this 
patient population is prone to the same barriers of many ASPs 
and thus should seek to find a balance between curtailing 
overuse of broad-spectrum antimicrobial therapy while pro-
viding adequate therapy.
Webb and colleagues conducted a quasi-experimental pre- 
and postimplementation of 2 antimicrobial stewardship inter-
ventions in a hematological malignancy treatment unit [23]. 
The interventions consisted of monthly antibiotic cycling for 
empiric treatment of febrile neutropenia and use of a clin-
ical prediction rule to guide empiric vancomycin-resistant 
Enterococcus faecium (VRE) therapy [42]. The primary outcome 
for the antimicrobial cycling intervention was antipseudomonal 
carbapenem consumption in days of therapy per 1000 patient-
days. The primary outcome for the VRE therapy prediction score 
intervention was days of daptomycin therapy per 1000 patient-
days. Both outcomes were analyzed using an interrupted time-
series regression analysis. Secondary outcomes included VRE 
colonization per 1000 admissions, inpatient mortality, and clin-
ical infections due to VRE, ESBL-producing Enterobacterales, 
phenotypically suspected AmpC-harboring Enterobacterales, 
methicillin-resistant Staphylococcus aureus (MRSA), and CDI.
As outlined in Table 1, the interventions resulted in a signifi-
cant decrease in carbapenem use and improved susceptibility in 
Pseudomonas aeruginosa isolates postintervention. In turn, this 
intervention likely also resulted in a decrease in daptomycin use 
attributable to lower rates of VRE colonization and subsequent 
VRE infections. The study also examined community ecology 
data in order to determine if changes in infection rates pre- and 
postimplementation were due to the antibiotic cycling interven-
tion vs changes in local microbiology. The findings of this study 
lend support to antibiotic cycling as it pertains to carbapenem 
and daptomycin usage while not adversely impacting clinical 
outcomes in the management of febrile neutropenic patients. It 
is notable that the success of the program was facilitated by an 
ASP pharmacist and close partnership with clinician leadership 
to advance the stewardship initiatives.
Implementation of Electronic Stewardship Tools
Reporting to the National Healthcare Safety Network (NHSN) 
Antimicrobial Use (AU) Option is specifically recommended 
to facilitate AU benchmarking [5]. However, Graber and col-
leagues note NHSN report limitations in the areas of facility 
matching, AU by infection diagnosis, and temporal assessment 
of antimicrobial prescribing [24].
The authors attempted to overcome these limitations through 
creation of AU visualization tools. The graphical displays were 
built on a foundation of both disease state and time frame. 
Pneumonia, urinary tract infection, and skin/soft tissue infec-
tion (PUS) were identified by ICD-9 and ICD-10 codes. Time 
frame was described as choice, change, and completion (CCC), 
representing the major AU decision points of empiric therapy, 
de-escalation, and definitive course, respectively. Based on col-
laborative feedback from 1 physician and 1 pharmacist steward 
at each of 8 Veterans Affairs (VA) facilities, the dashboards were 
updated to include data on antimicrobial type and unit and to 
allow for comparison across all or select VA sites. The stewards 
implemented ASP initiatives at their respective facilities based 
on needs identified by these individualized dashboards.
Reductions in total antimicrobial, anti-MRSA agent, and 
antipseudomonal agent utilization were noted at intervention 
facilities with statistically significant differences observed in 
total and antipseudomonal agent use. Despite the resource-
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results suggest that this type of tool would be effective for in-
dividualized, targeted ASP work across large health systems or 
networks. Additionally, the novel CCC framework allows for a 
unique drilldown on suboptimal antimicrobial prescribing at 
precise points in the AU continuum. Overall, the dashboard 
visualization approach allows for targeted selection of ASP 
interventions from a robust data source across all ASP stages 
regardless of previously implemented interventions.
DISCUSSION
As antimicrobial resistance, health care costs, and demands on 
stewardship programs continue to increase, stewards are chal-
lenged to implement creative solutions for improving patient 
care and antimicrobial use. Included here are 13 examples of 
novel stewardship interventions, representing a wide range of 
therapeutic areas, stewardship metrics including process out-
comes and antimicrobial use, and documentation of stew-
ardship interventions in inpatients and outpatients and in 
nonacademic medical centers.
Because of the wide variety of stewardship practices, the de-
velopment of “best practices” of specific interventions can be 
difficult to implement across the board. Although there are an 
increasing number of ASP publications yearly, including those 
focused on interventions and outcomes, it is important for stew-
ards to continue to report their innovative interventions and 
solutions to health care problems. Familiarity with these key, 
impactful interventions can provide a blueprint for teaching or 
intervention opportunities for stewards across the spectrum of 
experience and practice sites.
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